Susan M. Clardy
Susan M. Clardy has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Alex Uttard
Mersana Therapeutics, Cambridge, Massachusetts
19 shared publications - Bingfan Du
Mersana Therapeutics, Cambridge, Massachusetts
19 shared publications - David H. Lee
Mersana Therapeutics, Cambridge, Massachusetts
19 shared publications - Dokyong Kim
Mersana Therapeutics, Cambridge, Massachusetts
19 shared publications - Dorin Toader
Mersana Therapeutics, Inc., Cambridge, Massachusetts
19 shared publications - Elizabeth Ditty
Mersana Therapeutics, Inc., Cambridge, Massachusetts
19 shared publications
Latest Publications
- 16 October 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (21) , 24889-24895
Site-Specific Bioconjugation in Antibody−Drug Conjugates: From Conjugation Chemistry to Precision Molecular Design
- 16 October 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (21) , 24889-24895
Site-Specific Bioconjugation in Antibody−Drug Conjugates: From Conjugation Chemistry to Precision Molecular Design
- Open Access
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Supplemental Data File 1 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
Complete synthetic route for Monomeric Dolasynthen linker-scaffold-payload
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Data File 1 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
Complete synthetic route for Monomeric Dolasynthen linker-scaffold-payload
- Open Access
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Figure S3 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
Figure S3 shows body weights of animals at two doses
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
Figure S3 shows body weights of animals at two doses
- Open Access
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Table S4 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
Table S4 compares the nominal DAR to the calculated DAR values from measured Cmax values for each ADC
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
Table S4 compares the nominal DAR to the calculated DAR values from measured Cmax values for each ADC
- Open Access
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Figure S2 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
Figure S2 shows a graphical representation of IC50 spread over range of cytotoxicity experiments
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
Figure S2 shows a graphical representation of IC50 spread over range of cytotoxicity experiments
- Open Access
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Figure S4 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
Figure S4 compares the body weights of mice dosed with DAR2 and DAR18 ADCs at matched payload and antibody doses
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
Figure S4 compares the body weights of mice dosed with DAR2 and DAR18 ADCs at matched payload and antibody doses
- Open Access
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Table S3 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
Table S3 contains response numbers for in vivo efficacy study
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
Table S3 contains response numbers for in vivo efficacy study
- Open Access
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Table S3 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
Table S3 contains response numbers for in vivo efficacy study
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
Table S3 contains response numbers for in vivo efficacy study
- Open Access
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Figure S4 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
Figure S4 compares the body weights of mice dosed with DAR2 and DAR18 ADCs at matched payload and antibody doses
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
Figure S4 compares the body weights of mice dosed with DAR2 and DAR18 ADCs at matched payload and antibody doses
- Open Access
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Table S2 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
Table S2 supplies IC50 values for ADCs over a range of in vitro cytotox assays
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
Table S2 supplies IC50 values for ADCs over a range of in vitro cytotox assays